Close Menu

Genewiz

Genewiz, a contract research organization specializing in sequencing and other genomic services, has announced that it is branching out into the clinical sequencing and personalized medicine space with two sequencing panels — a 25-gene general pharmacogenomic panel and a 35-gene

Genewiz, a contract research organization specializing in sequencing and other genomic services, is branching out into the clinical sequencing and personalized medicine space and is planning to introduce two targeted sequencing-based tests in the coming months.

NEW YORK (GenomeWeb News) – Life Technologies has added 11 new members from the US and Canada to its Ion AmpliSeq Exome Certified Service Provider program, the company said today.

NEW YORK (GenomeWeb News) – Genewiz today announced a deal with BeiGene for the use of Genewiz's cancer panels to accelerate cancer biomarker discovery.

NEW YORK (GenomeWeb News) – Genewiz and the John Theurer Cancer Center at Hackensack University Medical Center today announced a collaboration for the discovery of ovarian cancer biomarkers.

NEW YORK (GenomeWeb News) – Genewiz and KeyTest Diagnostics today announced a collaboration aimed at developing molecular diagnostic tests for the Chinese market.

NEW YORK (GenomeWeb News) – Investment bank Jefferies this week upgraded Bruker's stock to Buy from Hold and upped its price target on the stock from $20 to $25.

Genewiz is now offering Illumina's TruSeq Cancer Panel and Life Technologies' Ion AmpliSeq Cancer Panel on the MiSeq and PGM, respectively.

NEW YORK (GenomeWeb News) – DNA testing contract research organization GeneWiz today said that it has obtained Clinical Laboratory Improvement Amendments licensure and certificate of registration from New Jersey, allowing it to offer clinical genomic testing.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.